University of Michigan, 2800 Plymouth Rd, B14 G214, 48109-2800, Ann Arbor, MI, USA.
University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
J Thromb Thrombolysis. 2022 Aug;54(2):197-210. doi: 10.1007/s11239-022-02643-3. Epub 2022 May 17.
Thromboembolism is a common and deadly consequence of COVID-19 infection for hospitalized patients. Based on clinical evidence pre-dating the COVID-19 pandemic and early observational reports, expert consensus and guidance documents have strongly encouraged the use of prophylactic anticoagulation for patients hospitalized for COVID-19 infection. More recently, multiple clinical trials and larger observational studies have provided evidence for tailoring the approach to thromboprophylaxis for patients with COVID-19. This document provides updated guidance for the use of anticoagulant therapies in patients with COVID-19 from the Anticoagulation Forum, the leading North American organization of anticoagulation providers. We discuss ambulatory, in-hospital, and post-hospital thromboprophylaxis strategies as well as provide guidance for patients with thrombotic conditions who are considering COVID-19 vaccination.
血栓栓塞是 COVID-19 感染住院患者的常见且致命的后果。基于 COVID-19 大流行之前的临床证据和早期观察报告，专家共识和指导文件强烈鼓励对 COVID-19 感染住院患者使用预防性抗凝治疗。最近，多项临床试验和更大规模的观察性研究为 COVID-19 患者的血栓预防方法提供了证据。本文档为北美主要的抗凝治疗提供者抗凝论坛提供了 COVID-19 患者使用抗凝治疗的更新指南。我们讨论了门诊、住院和住院后血栓预防策略，并为考虑 COVID-19 疫苗接种的血栓性疾病患者提供了指导。
